Alexander Vukasin: Great. Thank you. And one, I just wanted to kind of build off the last question there. So just curious on how you intend to grow placements in ’24. I guess just given like micro headwinds or whatnot, like there are some initiatives that have been coming into play in the near future, or some marketing efforts, anything of that sort? Thanks.
Brad Gray: Well, as I said and maybe the answer to an earlier question, we’re seeing a market that in spatial biology that has extraordinarily – extraordinary secular growth. I mean we’re in a major adoption cycle of a new form of science. And these kind of new revolutions that, are often declared nature of method of a year, they play out over a seven to 10-year time frame. So, we’re right in the steep part of the curve of the adoption cycle here. So, I think the secular growth of spatial biology, will be the most important driver of continued momentum in 2024. Of course, on top of that, we have a very exciting series of product launches and a road map to support them that we should keep customers interested in our technology at the forefront.
The most important of those is the launch of our CosMx 6000 plex RNA assay, which will put our technology at 12 to 15 times higher plex than the competition. There’s already tremendous customer interest in that and that will, become available for shipment in the first quarter. And then on the GeoMx side, the recently launched GeoMx IO Proteome Atlas, which is five times higher plex than the other protein panels offered by other companies is driving a resurgence, and interest in that platform. So, I think the secular interest in spatial biology, combined with our specific and compelling product offerings, should be the key drivers of growth in 2024 on the instrument side. And then, I guess, maybe finally, we placed a tremendous number of CosMx instruments during 2023 that, will just be becoming active and utilizing consumables in 2024.
And so, we expect to see that – we expect that to drive spatial consumable growth, which has the benefit of also expanding our gross margins, in the way that Tom alluded, to in his prepared remarks. So I think those are the three big catalysts, the CosMx 6000, the GeoMx IPA and the activation and consumer utilization of our rapidly growing spatial biology installed base.
Alexander Vukasin: Great. Thank you. That’s very helpful.
Operator: [Operator Instructions] Your next question comes from the line of UBS. Please go ahead. Your line is open.
Unidentified Analyst : You have [Christian] on for John. I guess starting off on the CosMx in Europe. I know you guys previously put out some, I guess, you could say workarounds in terms of having customers kind of shift their samples to CROs in jurisdictions not affected, by the injection. I was just wondering if you can give any update and maybe, even if you can maybe possibly like quantify, how well that’s working, the customer reception to that, how it’s been, et cetera?
Brad Gray: Yes, so we obviously want science in Europe to continue to benefit from our market-leading CosMx Spatial Molecular Imager. We think it would be a tragedy for European science, if they were constrained to work on the less flexible offerings of our competitors. So, we’re working as flexibly as we can with those groups, to help them get access to our technology by shipping samples to either CROs or to NanoString located, so those samples can be processed where there’s no injunctions. And I had said we’ve had modest success on that. I think a number of our customers are still in the process, of figuring out how best to do that. And our customers have been very supportive of the company. And I’d say, overall, the scientific community, is rooting for NanoString, to succeed in our litigation and to maintain choice in the marketplace.
